How to recover the damage caused by the epidemic?
Release time:
2020-07-15
Due to the impact of the new coronavirus epidemic, most industries and enterprises in China experienced an unprecedented "severe winter" test in the Spring Festival of 2020. Even at the moment, more than a month after the resumption of work, the market is at a standstill, the logistics is not smooth, the employee arrival rate, the rate of resumption of work is still an important factor that plagues the enterprise. The economic "shutdown" for more than two months has greatly damaged the vitality of many enterprises, and even many enterprises are facing the dilemma of being helpless. Since mid-February, the focus of national policy has been adjusted to promote the resumption of work and production. Among the eight initiatives proposed at the meeting on February 23 to promote the prevention and control of the new coronary pneumonia epidemic and the deployment of economic and social development, the precise resumption of work and production ranked first. In the recent meetings of the Group, "taking back the losses caused by the epidemic" has also become the most important topic.
So, how can we recover the damage caused by the epidemic?
Look for opportunities in the "harsh winter. The long-running epidemic has hit most companies with no difference, and whether they are good or bad, "getting through" is a major victory. This also means that many industries are passively shuffled, and the market structure will inevitably change. And these changes will be highlighted after the end of the epidemic. Therefore, as we stand the test of the epidemic, we are also faced with new market choices and opportunities, and the key is whether we can see or grasp them. Since the resumption of work, governments at all levels have introduced a number of preferential policies for enterprises to reduce the burden on the return of the market. Enterprise managers should make full use of this opportunity, carefully analyze the market, accurately grasp the trend, and seize those fleeting development opportunities.
is active at "stagnation. In order to get rid of the influence of market stagnation, it is impossible to rely on one enterprise and one link alone. It needs the synergy of the upstream and downstream of the industrial chain and peer enterprises to effectively "activate", which also brings more thinking space to the work of enterprises. For example, in accordance with the requirements of Pu'er City, concrete enterprises mask stock reached 200 before they can resume work, Yunnan peak in mid-February to the local mixing station to give masks, to help them solve the problem of resumption of work at the same time also activated their own downstream market, a small move to make a game of chess "live" up.
Practice internal skills in "idle" time. Because of the impact of the epidemic, many enterprises production, sales pressure plummeted, rare to have "free". This long period of "idle" is easy to let people loose, bring many negative effects. But at the same time, we also have more time than in the past to check and fill the gaps, discover and solve problems, have more time than in the past to train and learn to improve the professional quality of employees, and have more time than in the past to study and think about the future development of the enterprise. No matter management cadres or ordinary employees, they should not let these "idle" be wasted, but should play a positive role in improving their health level and enhancing their "immunity" for future development ".
Innovation management in the "closed" period. Since the resumption of work for more than a month, many people have a deep understanding of the inconvenience caused by the "closure. "Closed" directly affects our work efficiency, and it is not the focus and breakthrough of our management innovation. Not long ago, pharmaceutical sales companies used the form of "online classes" to conduct business training for marketers, and health technology companies participated in online "cloud exhibitions". These are all good practices that have never been done before, but have achieved certain results. If there are more similar innovations and breakthroughs, and if we encounter other "extraordinary environments" in the future, we will be able to do it with ease.
Of course, the string of epidemic prevention and control still cannot be relaxed while we are hard at resuming work and recapturing losses. With the development of the epidemic, the focus of prevention and control has shifted to "anti-import", provinces outside Hubei have lowered the level of emergency response, the arrival of spring also let many people breathe a sigh of relief. However, from the perspective of the international environment, the epidemic prevention and control situation is still grim, more or less will always have an impact on the country. Therefore, as long as the epidemic is not over, we cannot be paralyzed and lax; even after the new crown epidemic has passed, it is very necessary for enterprises to strengthen health and epidemic prevention management and for employees to develop good health and epidemic prevention habits. (Hong Tao)
More information
Yunnan peak through the safety standard secondary acceptance
On March 21, Yunnan Jianfeng Cement Company successfully passed the evaluation and acceptance of secondary enterprises for safety production standardization. On the same day, a review team composed of leaders of the Yunnan Provincial Work Safety Supervision Bureau and relevant experts reviewed the implementation of the establishment of Yunnan Jianfeng safety production standardization secondary enterprises. According to the 13 elements involved in the "Standard for Assessment and Rating of Safety Production Standardization in Cement Enterprises", the review team conducted strict assessment and scoring item by item through grouping to check the site and review the data, and finally determined that Yunnan Peak passed the standard acceptance of safety standardization secondary enterprises. Yunnan Jianfeng has always attached great importance to safety production. After passing the three-level safety standard enterprise review in 2015, in order to raise the level of enterprise safety management to a new level, in 2016, it began to create secondary safety standardization. Over the past year, Yunnan Jianfeng has insisted on taking the creation of secondary safety standards as the top priority of production and operation management, and has formulated an implementation plan for production safety standardization in accordance with the requirements of national standardization norms. the content covers production safety responsibility system, education and training, safety inspection, safety facilities management and other safety production management standards, systems and post safety operation procedures, while further strengthening daily safety inspection and regularly organizing emergency plan drills, strengthen the investigation and rectification of potential safety hazards and the supervision of important hazard sources, and further consolidate the foundation of enterprise safety production management. After the review, Zhou Jiping, general manager of Yunnan Jianfeng, said that Yunnan Jianfeng will take this standard as a new starting point. On the basis of consolidating the accident-free achievements in production safety for two consecutive years, it will conscientiously implement the main responsibility of production safety and cultivate
2020
07-30
Pharmaceutical Company Invests in Beihui Bio-Peak Pharmaceutical Plate to Expand its Territory
News from our newspaper On February 28, the 10th meeting of the 9th Board of Directors of the Group Company reviewed and approved the "Proposal on Foreign Investment of Subsidiaries" and the "Proposal on Authorizing the Chairman of the Board of Directors." On the same day, Jianfeng Pharmaceutical signed the "Agreement on Capital Increase and Share Transfer of Beijing Huibaoyuan Biotechnology Co., Ltd." and the "Performance Commitment Compensation Agreement" with relevant parties. It is planned to use Beijing Huibaoyuan Biotechnology Co., Ltd. (Beihui Biotechnology) and its holding subsidiary Guangxi Huibaoyuan Pharmaceutical Technology Co., Ltd. (Guanghui Pharmaceutical) as a platform to jointly carry out new drug research and development, drug production and operation and other pharmaceutical business cooperation. Beihui Biological formerly known as Beijing Huibaoyuan Biotechnology Co., Ltd. The company has strong capabilities in new drug research and development. The actual controller is James Zhou (Zhou Hua), a returned entrepreneurial Ph.D. from Yale University in the United States, and hired Professor Zheng Yongqi from Yale University in the United States as the director of the Huibaoyuan Science and Technology Committee, focusing on anti-tumor and liver disease research. Through the cooperation with Yale University, we have obtained the patent authorization and commercial development license of the new anti-cancer chemical drug trasatabine (trokacitabine)(which has obtained the national new drug clinical approval in August 2016), the anti-hepatitis B chemical drug Crevudine (Clevudine). Guangxi Huibaoyuan Pharmaceutical Technology Co., Ltd., a subsidiary of Beihui Biology, is located in the third international park "China-Malaysia Qinzhou Industrial Park" jointly built by the Chinese government and foreign governments in Guangxi. It covers an area of 214.46 mu and has production workshops for multiple dosage forms such as percolation, tincture, solid preparations and liquid preparations.
2020
07-31
Peak health marketing and a new "play"
Building a New System, Flattening Management, Spike Health Marketing, New "Fit" On February 17, Spike Health Technology Company held a sales meeting to integrate and adjust the construction of a new marketing system and deploy and implement the 2017 sales work. Chen Daiyou, general manager of Health Technology Company, carefully explained and answered the marketing system construction and sales management assessment methods at the meeting, and reached a consensus on unifying thinking. The sales business of Health Technology Company involves three categories: health care products, plant extracts and Chinese herbal pieces. The product attributes and categories are different, and the product sales channels are diversified. In order to facilitate market expansion and adapt to the rapid response to market changes, the Company focuses on key products, key channels and key markets, adjusts the original division model, combines all sales businesses of the Company, establishes a marketing center, and centralizes and unifies flat management. At the meeting, the Health Technology Company issued the "2017 Sales Management Assessment Measures", which takes sales performance as the leading factor, defines the sales staff's business expenses and market expansion support policies, implements quarterly and annual assessment of sales targets, and directly links the assessment of the progress of sales staff's target tasks with monthly income. After two-way selection, adjustment and implementation of sales positions and target tasks, all sales staff of Health Technology Company have signed a sales economic responsibility system. Chen Daiyou hopes that marketers will build confidence to meet the challenges and grow and progress together with the enterprise. At the same time, he said that the health technology company will focus on strengthening the construction and cultivation of the sales team, and carry out training, learning and experience sharing in various ways, so as to improve the business ability and level of the sales team. (Spike Health)
2020
07-31
Peak health marketing and a new "play"
Building a New System, Flattening Management, Spike Health Marketing, New "Way to Work" On February 17, Spike Health Technology Company held a sales meeting to integrate and adjust the construction of a new marketing system and deploy and implement the 2017 sales work. Chen Daiyou, general manager of Health Technology Company, carefully explained and answered the marketing system construction and sales management assessment methods at the meeting, and reached a consensus on unifying thinking. The sales business of Health Technology Company involves three categories: health care products, plant extracts and Chinese herbal pieces. The product attributes and categories are different, and the product sales channels are diversified. In order to facilitate market expansion and adapt to the rapid response to market changes, the Company focuses on key products, key channels and key markets, adjusts the original business model, unifies all sales businesses of the Company, establishes a marketing center, and centralizes and unifies flat management. At the meeting, the Health Technology Company issued the "2017 Sales Management Assessment Measures", which takes sales performance as the leading factor, defines the sales staff's business expenses and market expansion support policies, implements quarterly and annual assessment of sales targets, and directly links the assessment of the progress of sales staff's target tasks with monthly income. After two-way selection, adjustment and implementation of sales positions and target tasks, all sales staff of Health Technology Company have signed a sales economic responsibility system. Chen Daiyou hopes that marketers will build confidence to meet the challenges and grow and progress together with the enterprise. At the same time, he said that the health technology company will focus on strengthening the construction and cultivation of the sales team, and carry out training, learning and experience sharing in various ways, so as to improve the business ability and level of the sales team. (Spike Health)
2020
07-31
Accident-free factory creation enters "second season"
At the beginning of the new year, a major "highlight" of the company's safety and environmental protection management in recent years-the "second quarter" of the establishment of a safety and environmental protection accident-free factory has also begun. Safety and environmental protection accident-free factory creation activities are an important measure for the company to improve the level of on-site management. The first phase of the activity will start on January 1, 2014 and end at the end of 2016 for a period of three years. Since the launch of the activity, all subordinate enterprises of the company have actively organized publicity and training related to safety and environmental protection, strengthened the awareness of safety and environmental protection of all employees, improved the management and operation level of safety and environmental protection; increased investment in safety and environmental protection facilities and equipment; strengthened safety and environmental protection inspection and self-examination and correction of hidden dangers, and timely organized rectification of hidden dangers; strictly assessed the units and relevant responsible persons of the accident, And the accident situation in the group, in order to arouse vigilance and avoid similar accidents. In the past three years, the company's subsidiaries have achieved remarkable results in standardization, safety, and clean operation. Safety and environmental protection accidents have dropped significantly, and no major accidents have occurred, which has effectively promoted the company's safe and civilized production construction. In the 2016 safety and environmental protection accident-free factory establishment assessment conducted a few days ago, a total of 6 units met the accident-free factory standard, of which Yunnan Jianfeng, Jianfeng International Trade and Pharmaceutical Department met the standard for the second consecutive year, and Daye Jianfeng, Qiubin Factory and Cable Company met the standard in the first year. In order to sum up experience and further improve the level of safety and environmental protection management, the Group decided to continue to open
2020
07-31
What will the Chinese Medicine Act bring us?
At the 25th meeting of the Standing Committee of the 12th National People's Congress in December 2016, the the People's Republic of China Chinese Medicine Law (hereinafter referred to as the Chinese Medicine Law) was deliberated and passed, which will come into effect on July 1 this year. As the first comprehensive law that comprehensively and systematically embodies the characteristics of traditional Chinese medicine, the Law of traditional Chinese Medicine clearly stipulates the service of traditional Chinese medicine, the protection and development of traditional Chinese medicine, the training of talents of traditional Chinese medicine, and the scientific research of traditional Chinese medicine. With the change of people's health concept and the continuous innovation of medical mode in recent years, the role of traditional Chinese medicine in health is becoming more and more important. The promulgation of the "Traditional Chinese Medicine Law" has made the development of Chinese medicine more law-based, and it is bound to bring changes to domestic pharmaceutical companies. So, the peak of the pharmaceutical, health products companies will look at the "Chinese Medicine Law", and will have how to deal with it? A few days ago, the reporter interviewed the pharmaceutical companies and peak health technology companies related to the person in charge. What will the Chinese Medicine Act bring us? Reporter: As the general manager of Peak Pharmaceutical, what do you think of the Chinese Medicine Law? Huang Jinlong (Deputy General Manager of the Group Company and General Manager of the Pharmaceutical Company): the Law of traditional Chinese Medicine defines the important position and development policy of traditional Chinese medicine. The state encourages traditional Chinese medicine and western medicine to learn from each other, complement each other, coordinate development, give full play to their respective advantages, and promote the integration of traditional Chinese and western medicine. Traditional Chinese medicine is a huge knowledge system, reflecting the Chinese nation's understanding of life, health and disease. It is precisely because of the distinctive characteristics of Chinese medicine that the Law of Chinese Medicine is used in Chinese medicine clinics, Chinese medicine physicians and doctors.
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page